Table 1.
Patients pre-ART and on-ART follow-up characteristics, CMSDS, Abidjan, Côte d’Ivoire, 2003-2008
| Characteristics | N = 1008 | |
|---|---|---|
|
At ART initiation |
|
|
| Sex, female, n (%) |
673 |
(67) |
| Age (years), median (IQR) |
35.0 |
(29.7-41.9) |
| CD4 count (cell/mm3), median (IQR) |
186 |
(97–258) |
| WHO clinical stage 3 or 4, n (%) |
136 |
(13) |
| BMI (kg/m2), median (IQR) |
21.3 |
(19.1-23.9) |
| Patients on specific ART regimen, n (%) |
|
|
| 2NRTIs + nevirapine α |
562 |
(55.8) |
| 2NRTIs + efavirenz β |
332 |
(32.9) |
| 2NRTIs + ritonavir boosted PI* |
78 |
(7.7) |
| Others** |
36 |
(3.6) |
| Hemoglobin (g/dl), median (IQR) |
10.8 |
(9.4-12.1) |
| Patients with prior use of cotrimoxazole†, n (%) |
709 |
(70) |
|
Follow-up on ART |
|
|
| Cumulative (PY) |
2076 |
|
| Median (IQR), in months |
17.3 |
(5.7-38.0) |
| Death, n (%) |
47 |
(4.6) |
| Patients lost to follow-up‡, n (%) | 128 | (12.7) |
IQR, Interquartile Range; WHO, World Health Organization; ART, Antiretroviral Therapy; BMI, Body Mass Index; d4T, Stavudine, 3TC, Lamivudine; AZT, zidovudine; ddI, Didanosine; TDF, Tenovofir diproxil fumarate; FTC, Emtricitabine; ABC, Abacavir.
α: d4T + 3TC (n = 484), AZT + 3TC (n = 78).
β: AZT + 3TC (n = 234), d4T + 3TC (n = 56), TDF + FTC (n = 38), d4T + ddI (n = 2), ddI + 3TC (n = 1), ABC + 3TC (n = 1).
*: AZT + 3TC (n = 25), TDF + FTC (n = 12), d4T + 3TC (n = 4), ddI + ABC (n = 4), ddI + 3TC (n = 1), ABC + 3TC (n = 1)] + lopinavir/ritonavir (n = 47); AZT + 3TC (n = 21), d4T + 3TC (n = 10)] + indinavir/ritonavir (n = 31).
**: 3NRTIs (n = 30) : TDF + FTC + AZT (n = 28), AZT + 3TC + ABC (n = 2); Non-boosted PIs (n = 6) : AZT + 3TC + indinavir (n = 3), AZT + 3TC + nelfinavir (n = 3).
†: Use of cotrimoxazole at least once prior to antiretroviral initiation.
‡: Lost to follow-up: patients whose last contact with the study center was prior to 31 Dec 2008, and who were not found to be deceased, alive, or transferred out up to August 31st 2009.